All News
Opening Day Report
The opening of ACR2 Convergence was a hit for all who signed up and viewed in. The day included the presidential address by outgoing president Dr. David Karp (UT Southwestern) and a keynote talk and interview with Dr. Seema Yasmin (Stanford).
Read Article
Emerging Therapies in Spondyloarthritis: A Promising Pipeline
Growing awareness of spondyloarthropathies over the last two decades has led to a better understanding of the pathophysiology of spondyloarthritis, and subsequently increased interest in more distinct, disease state specific treatment options.
Read Article
👉Get contrast if ordering an MRI to eval for inflamm. arthritis
👉Heel spur vs. enthesitis? Look for erosions at dorsum of calcaneus & other signs of inflamm
👉DISH vs. axial PsA? DISH➡️contiguous bony ossific'n up anterior margin of the vertebral bodies; PsA not cont.
TheDaoIndex KDAO2011 ( View Tweet)
KEEPsAKE trial 1 (DMARD-IR) and 2 (DMARD/biologic-IR) on risankizumab (IL23i) for PsA:
👉some benefits of risankizumab for axial disease
👉no data regarding bowel disease
👉pts did remain on background DMARDS, steroids.
(2/2)
TheDaoIndex KDAO2011 ( View Tweet)
Excellent talk by Dr. Anna Molto. Characteristics of spondyloarthritis, noting some patients with PsA have radiographic and non-radiographic axial SpA.
#ACR21 6S403 @RheumNow https://t.co/ycftOMrWO9
Pedro Castillo _Castillo_Pedro ( View Tweet)
Are we getting closer to personalised medicine in #psoriaticarthritis Predicting progressors vs non-progressors using proteomics identified 103 candidate biomarker peptides that will discriminate the two groups @RheumNow #ACR21 #ACRBest Abst#0449 https://t.co/obDXTz3i5N
Dr. Antoni Chan synovialjoints ( View Tweet)
Excellent scientific session on #SpA at #ACR21 right now- especially like this clear diagram of pathophysiology and useful summary slide from Dr Nigil Haroon on differences between #axSpA and axial #PsA
@RheumNow https://t.co/F7Ns7e9HQI
Mrinalini Dey DrMiniDey ( View Tweet)
“The differences and similarities between axial disease in psoriatic arthritis vs axial spondyloarthritis is just at the cusp of discovery” Nigil Haroon at session 6S403 @RheumNow #ACR21
Dr. Antoni Chan synovialjoints ( View Tweet)
Tyk2/Jak1 inhibitor brepocitinib in PsA. Looks good. Works for skin, joints, enthesitis, dactylitis, and PROs. No unexpected safety signals. Abstr#0488 #ACR21 @RheumNow https://t.co/MIOLw8BABN
Richard Conway RichardPAConway ( View Tweet)
Risankizumab (IL-23i) KEEPsAKE 1 and 2 (phase 3) studies for PsA treatment
⬆️ACR20 response compared to pbo
⬆️secondary endpoints
⭐️no new safety signals
Abs#453
#ACR21 #ACRBest @RheumNow
https://t.co/7bwvIPMz38 https://t.co/TJaSqwipa5
Robert B Chao, MD doctorRBC ( View Tweet)
#ACR21 #ACRBest @Rheumnow
Abst #0452 Raychaudhuri et al.
TB-PET/CT indices ➡️ disease outcome measures in PsA
Identifies synovitis, enthesitis, dactylitis, nail matrix inflammation of PsA as compared to RA and OA
Future use as a diagnostic tool for early disease of PsA https://t.co/uLsAWEkboS
swethaann23 swethaann23 ( View Tweet)
Can we predict who which PsA pts will be radiographic progressors?
Abs#449 identified 103 candidate biomarker peptides corresponding to 69 proteins that could ID progressors
More data needed
#ACR21
@RheumNow
https://t.co/OLfPRNjTKV https://t.co/6UTn1J7nJH
Robert B Chao, MD doctorRBC ( View Tweet)
New treatments in #psoriaticarthritis Brepocitinib TYK 2/JAK 1 inhibitor had superior efficacy vs PBO in active PsA at Week 16, with improvements in more refractory domains over 52 weeks. Safety consistent with other JAKi @RheumNow #ACR21 Abstr#0488 https://t.co/ugsV7uRwro
Dr. Antoni Chan synovialjoints ( View Tweet)
Interesting study on immune cell profiling in PsA pts
⭐️variability in T cell sub-populations in PsA pts
⭐️no difference in lymphocyte cell populations before/after therapy
Abs#0056
https://t.co/16PYxaxT2S
#ACR21
@RheumNow https://t.co/dWaJr7hJ1p
Robert B Chao, MD doctorRBC ( View Tweet)
#ACR21 Abst#0453. KEEPsAKE: Risankizumab (Skyrizi) monoclonal Ab inhibits IL23 by binding p19.
▶️150 mg RZB vs Placebo
⭐️RZB: higher ACR20/50/70, PASI90, HAQ-DI
⭐️Resolution of enthesitis, dactylitis. Improve fatigue, fxn
⭐️No safety signal
https://t.co/bqQJ4Zr7o5 @Rheumnow https://t.co/2ZfGRs2GUd
Links:
Eric Dein ericdeinmd ( View Tweet)
KEEPsAKE trial 1 (DMARD-IR) and 2 (DMARD/biologic-IR) on risankizumab (IL23i) for PsA:
👉phase 3 DBRPCT 24 weeks
👉150 mg week 0,4, 16 weeks
👉improved ACR20,ACR50,ACR70
👉improved PASI90
👉improved HAQ-DI
👉no increased safety signals
#ACR21 Abstr#0438 #Plenary @rheumnow https://t.co/ioIBXgV4Hi
TheDaoIndex KDAO2011 ( View Tweet)
Promising results of Risankizumab for #psoriaticarthritis
🔸Pts significantly achieved higher rates of ACR20, 50 and 70 response at wk 24 vs. placebo
🔸Well tolerated and showed no safety signals
@RheumNow #ACR21 #ACRBest abs0453 https://t.co/TDSLEgF68g
sheila RHEUMarampa ( View Tweet)
Abst0453 #ACR21 @RheumNow integrated phase 2/3 trial results of il23 inhibitor Risankizumab (RZB) in PsA: significant improvement ACR20 at Week 24 (RZB 55.5% vs PBO 31.3%, P < 0.001), secondary endpoint met at HAQ DI, PASI, fatigue score& enthesitis. no new safety signals https://t.co/ZAVgswoXCf
Olga Petryna DrPetryna ( View Tweet)
RZB tx resulted in statistically greater improvements in signs/ symptoms of PsA vs PBO and was well tolerated w/ no new safety signals. Plenary Abs 0453 #ACR21 #RheumNow #ACRbest @RheumNow https://t.co/c9RJdWlmpO https://t.co/MDbdAhdnIy
Dr. Rachel Tate uptoTate ( View Tweet)
New treatments in #psoriaticarthritis Deucravacitinib TYK2 inhibitor selectively mediates cytokine signaling, specific inflammatory pathways (eg, IL-23, IL-12, and Type I interferons) concomitant with clinical symptom improvement @RheumNow #ACR21 Abst#0490 https://t.co/7JZGa5R4eC
Dr. Antoni Chan synovialjoints ( View Tweet)
